Brief: Rhythm Pharmaceuticals Announces First Patients Dosed In Phase 2 Trial For Oral Mc4r Agonist Lb54640
23/07/2024 13:23
July 23 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O :
* RHYTHM PHARMACEUTICALS ANNOUNCES FIRST PATIENTS DOSED IN
PHASE 2
TRIAL EVALUATING ORAL MC4R AGONIST LB54640 IN HYPOTHALAMIC
OBESITY
* RHYTHM PHARMACEUTICALS INC: LB54640 HAS SHOWN TARGETED
EFFECT ON
MC4R WITHOUT HYPERPIGMENTATION
Source text for Eikon: ID:nGNX3xxz4k
Further company coverage: RYTM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand